News | October 22, 2021
Gland Pharma PAT declines to Rs 302 crore QoQ in Q2FY22
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The Amplitude Solution gives laboratories the ability to scale Covid-19 PCR testing and process up to 8,000 samples a day
It is the first presbyopia-correcting lens implant for cataract surgery
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
Subscribe To Our Newsletter & Stay Updated
